Case Reports
Vol. 13 No. 1 (2021): Mediterranean Journal of Hematology and Infectious Diseases, Volume 13, 2021
Ibrutinib associated cardiovascular events in a patient wearing an implanted loop recorder
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: May 3, 2021
Accepted: May 28, 2021
Accepted: May 28, 2021
940
Views
301
Downloads
104
HTML
Authors
Ibrutinib is a well-tolerated and effective therapy used for the treatment of chronic lymphocytic leukemia (CLL). Its use has been associated with cardiovascular events such as atrial fibrillation (Afib), hypertension, and ventricular arrhythmias. Implanted loop recorders are a useful tool in guiding the management of patients with cardiac arrhythmias.
Downloads
Download data is not yet available.
Citations
Burger, J.A., et al., Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia, 2020. 34(3): p. 787-798.
Munir, T., et al., Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol, 2019. 94(12): p. 1353-1363.
McMullen, J.R., et al., Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood, 2014. 124(25): p. 3829-30.
Xiao, L., et al., Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. Circulation, 2020. 142(25): p. 2443-2455.
Dickerson, T., et al., Hypertension and incident cardiovascular events following ibrutinib initiation. Blood, 2019. 134(22): p. 1919-1928.
Leong, D.P., et al., The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood, 2016. 128(1): p. 138-40.
Thompson, P.A., et al., Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood, 2016. 127(3): p. 303-9.
Guha, A., et al., Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies. J Am Coll Cardiol, 2018. 72(6): p. 697-698.
Maddocks, K.J., et al., Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol, 2015. 1(1): p. 80-7.
How to Cite
“Ibrutinib associated cardiovascular events in a patient wearing an implanted loop recorder” (2021) Mediterranean Journal of Hematology and Infectious Diseases, 13(1), p. e2021044. doi:10.4084/MJHID.2021.044.
Copyright (c) 2021 Daniel Rivera, Koichi Takahashi, Jean-Benard Durand, Alessandra Ferrajoli
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
